The Premier Buying Network for Medical Spas & Aesthetic Physicians


  Contact : 1.844.799.2384

All Posts Tagged: Dermatology

An Aesthetic Provider’s Guide to Identifying the Brown Spots You WANT to Treat: SKs!

Learn How to Identify, Treat, and Become Profitable When Addressing SKs

A board-certified dermatologist is a medical doctor who specializes in the diagnosis and medical and cosmetic treatment of skin, hair and nail conditions. However, many of the same patients who visit Dermatologists are the same patients that walk through the doors of a medical spa or plastic surgery practice. As an aesthetic medical provider, especially one who treats other skin conditions or offers cosmetic procedures, it’s critical to know the difference between Seborrheic Keratoses (SKs, raised brown spots or age spots) and potentially harmful skin conditions. With nearly 80% of the patients who walk through your door affected by SKs, it’s also an exciting opportunity to offer a new treatment which can reduce or remove the appearance of brown spots or age spots.

SO, WHAT ARE SEBORRHEIC KERATOSES?

SKs are common, benign skin growths that can occur anywhere on the body. Although anyone can develop SKs, they’re typically more prevalent with age. SKs, more commonly known as raised brown spots or ‘age spots’, can vary in size, appearance and coloration although they tend to have a waxy, stuck-on-the-skin appearance. SKs may also look like other common skin growths including warts, actinic keratoses (which are generally dry and/or scaly growths and can become harmful), moles, and of course, melanoma. If you have any question as to whether a spot is an SK or another type of skin condition, it’s always recommended that you send your patient to a board-certified dermatologist.1

WHO GETS SKs AND WHERE DO PATIENTS FIND THEM?

SKs typically occur in middle age or later and may appear in anyone (or any skin type) at any time. They’re most commonly found on the chest, back, scalp, face and neck although they can appear almost anywhere on the body, with the exception of the palms of the hands and the soles of the feet.1  

WHY DO PATIENTS GET SKs?

The number of SKs found on a patient tends to increase with age, but the exact cause of SKs is unknown.1

WHAT’S THE BEST WAY TO TREAT SKs?

In a recent study, 73% of participants said they were mostly or slightly bothered by the appearance of SKs around their face, neck or hairline2. With this becoming a more popular (or widely-discussed) skin condition, many patients look to remove their visible or irritated SKs. In-office options for removing SKs include cryotherapy (freezing), electrosurgery or curettage (electric currents or scraping), topical treatments (hydrogen peroxide), and laser treatments, all of which have the risk of scarring and/or infection.1

BETTER RESULTS AND BETTER RETURNS WITH THE NEWEST SK TREATMENT

Until very recently, providers have not had access to a painless topical solution that has proven to successfully clear SKs. ESKATA, developed by Aclaris, is the first and only FDA-approved topical treatment indicated for SKs. With fewer side effects and better outcomes, it is quickly becoming a popular treatment not only in Dermatology practices, but in other types of aesthetic medical facilities.  As ESKATA can be administered by both physicians and mid-level providers, it offers a unique opportunity to provide a solution to a large portion of aesthetic patients with a 2:1 return (better than injectables).

To learn more about the clinical and financial benefits of using ESKATA, please contact us at info@medresultsnetwork.com or visit us here. Members receive a 15% quarterly rebate on ESKATA purchases.  

Reference 1: American Academy of Dermatology. Seborrheic Keratoses. 2018
Reference: 2. Data on file. Aclaris Therapeutics, Inc. 2018.

Read More

MRN Forms Exclusive Partnership With Strata Skin Sciences

STRATA Skin Sciences Announces Agreement with MedResults Network, a GPO Exclusive to the Aesthetic Medical Market

Agreement will enhance sales efforts of Nordlys and Stratapen

Horsham, PA, October 16, 2017 — (NASDAQ: SSKN) STRATA Skin Sciences, Inc. (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced signing an Agreement with MedResults Network (MRN). MRN is a Group Purchasing Organization that has more than 3,000 members including Dermatology Offices, Plastic Surgery Practices, Facial Plastic Practices, MediSpas and other providers. MRN researches product categories and selects advantaged products and then negotiates pricing for its membership. MRN focuses on the aesthetic market and has agreements with more than 50 vendors with only one vendor per product category.

Frank McCaney, President and Chief Executive Officer of Strata, commented:

“We are pleased to announce this relationship which we believe has major benefits to STRATA. MRN has a loyal and long term subscriber base and a reputation for providing value to its members. MRN provides additional value to its members by offering educational seminars and value to its vendors by active promotion of the products on agreement with them. Furthermore, the products that Strata introduced earlier this year in the Aesthetic space are outstanding products but lacked broad awareness. We believe that the reach and credibility of MRN will greatly benefit our sales efforts.”

Jeff Routledge, President of MRN added:

“We are excited about the opportunity to assist STRATA in marketing their products to our membership. STRATA’s Aesthetic products, Nordlys and Stratapen are excellent products that are in growing sectors of the Aesthetic market. MRN’s mission is to offer our members best-in-class products from world class companies through pricing that can only be achieved by leveraging the buying power of our 3,000 member practices and medical spas.”

The relationship between MRN and STRATA with special pricing to MRN members is being fully launched to the membership this week.

About STRATA Skin Sciences, Inc.

(www.strataskinsciences.com)

STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.  Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN™ MicroSystem, marketed specifically for the intended use of micropigmentation; and Nordlys, a multi-technology aesthetic laser device.

About MedResults Network

(www.medresultsnetwork.com)

MedResults Network is a free membership service that offers instant discounts and quarterly rebates at no risk or obligation. They have partnered with over 50 leading national vendors to negotiate cost savings for its members in product categories including fillers, lasers, skin care, and more. Since 2008 their leadership team worked closely with both their members and partners to ensure their continued growth and success.

Safe Harbor

This press release includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, including the Company’s ability to sell products to MRN members,  generate the anticipated revenue stream, the Company’s ability to generate sufficient cash flow to fund the Company’s ongoing operations beginning at any time in the future, the Company’s ability to license or acquire new products, the public’s reaction the Company’s new advertisements and marketing campaign, access to capital markets, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. The Company assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

 

Investor Contacts:

Christina L. Allgeier, Chief Financial Officer   Bob Yedid, Managing Director
STRATA Skin Sciences, Inc.   LifeSci Advisors, LLC
215-619-3267   646-597-6989
callgeier@strataskin.com   Bob@LifeSciAdvisors.com
Read More

Pin It on Pinterest